Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4164.70 +1.4% SILVER 56.66 +1.4% COPPER 6.54 −1.8% OIL 95.54 +0.5% PALLADIUM 1136.00 +3.6% EVI 0.500 +0.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.190 +0.0% TECT 1.66 +0.0% TOM 0.135 +0.0% FVL 0.900 +0.0% HART 0.195 +0.0% VLD 0.415 +0.0% TGOL 0.150 +0.0% TWR 0.170 +0.0% LAF 0.810 +0.0% SAO 0.050 +0.0% GOLD 4164.70 +1.4% SILVER 56.66 +1.4% COPPER 6.54 −1.8% OIL 95.54 +0.5% PALLADIUM 1136.00 +3.6% EVI 0.500 +0.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.190 +0.0% TECT 1.66 +0.0% TOM 0.135 +0.0% FVL 0.900 +0.0% HART 0.195 +0.0% VLD 0.415 +0.0% TGOL 0.150 +0.0% TWR 0.170 +0.0% LAF 0.810 +0.0% SAO 0.050 +0.0%
Earnings Routine +

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

Eupraxia Pharmaceuticals Secures H2 2028 Runway with Strong Clinical Data, But Phase 2b Catalyst Remains Key

By The Northwire Desk — AI Analysis May 12, 2026 · 17:00 EPRX · 10.51 EUPRAXIA PHARMACEUTICALS INC. J
Executive Summary
  • Eupraxia Pharmaceuticals reported First Quarter 2026 financial results on May 12, 2026.
  • Net loss for Q1 2026 was $12.7 million, an increase from $6.8 million in Q1 2025 due to higher R&D spend.
  • Total liquidity exceeds $140 million (Cash: $58.5M + Short-term investments: $80.4M).
  • Capital runway extends into the second half of 2028 based on existing reserves and warrant exercises.
  • Clinical update confirms robust response in the highest dose cohort (Cohort 9) of the RESOLVE trial for EP-104GI after 36 weeks.
  • Financing completed February 20, 2026: $63.2 million gross proceeds via public offering at $7.00 per share.
Material Impact
  • The news confirms the successful closing of the previously announced financing (Feb 18/20), removing immediate liquidity uncertainty.
  • Clinical data reiterates positive trends already presented at Digestive Disease Week (May 5-6, 2026) regarding tissue health and symptom improvement.
  • Liquidity position is strong relative to burn rate, reducing near-term dilution risk compared to peers with shorter runways.
  • The increase in net loss ($12.7M vs $6.8M YoY) reflects expected scaling of clinical operations but does not signal financial distress given the cash balance.
  • As this information largely confirms prior announcements (Financing and DDW data), it is categorized as Routine - Positive rather than a new market-moving surprise.
EPRX · Price
Company Overview
  • Company: Eupraxia Pharmaceuticals Inc., focused on gastrointestinal diseases using its Diffusphere delivery platform.
  • Flagship Project: EP-104GI, a long-acting submucosal corticosteroid formulation for Eosinophilic Esophagitis (EoE).
  • Development Stage: Phase 2b RESOLVE trial (randomized placebo-controlled) currently recruiting; Phase 1b/2a data shows dose-response relationship and durability.
  • Mechanism: Local delivery via injection to address inflammation and fibrosis in the esophageal tissue, aiming for a once-a-year treatment option.
Read the original news release →

More from EUPRAXIA PHARMACEUTICALS INC. J

May 06, 2026 · 07:00

Eupraxia Confirms Fibrosis Reversal in EoE, But Phase 2b Readout Remains Key Catalyst

Other May 05, 2026 · 07:00

Eupraxia Confirms Dose-Response in EoE Trial; Phase 2b Data Due Q4

Other Apr 22, 2026 · 07:00

Eupraxia Confirms Durable Efficacy and Safety Profile Ahead of Phase 2b Top-Line Readout

Other Apr 21, 2026 · 07:00

Eupraxia Durability Data Validates Lead Candidate, Yet Phase 2b Timing Shifts to Q4

Other Mar 17, 2026 · 12:41

Eupraxia posts 24-week data in high-dose Resolve cohort

Other Mar 17, 2026 · 07:00

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Other